Impact News +++ Universal Display Corporation Announces Quarterly Cash Dividend of $0.45 per Share (Business Wire) +++ UNIVERSAL DISPLAY Aktie -3,43%

APYX MEDICAL Aktie

>APYX MEDICAL Aktienkurs

2.87 EUR (Tradegate)

Ask: 2.94 EUR / 844 Stück

Bid: 2.8 EUR / 895 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

APYX MEDICAL Aktie über LYNX handeln

Intraday

1 Jahr

>APYX MEDICAL Performance

1 Woche: +4,2%

1 Monat: +39,2%

3 Monate: +59,8%

6 Monate: +141,1%

1 Jahr: +151,2%

laufendes Jahr: +72,5%

>APYX MEDICAL Aktie

Name:

APYX MEDICAL DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US03837C1062 / A2PBJC

Symbol/ Ticker:

BOV (Frankfurt) / APYX (NASDAQ)

Kürzel:

FRA:BOV, ETR:BOV, BOV:GR, NASDAQ:APYX

Index:

Webseite:

https://apyxmedical.com/

Profil:

Apyx Medical Corp. is an advanced energy technolog..
>Volltext..

Marktkapitalisierung:

106.4 Mio. EUR

Unternehmenswert:

114.85 Mio. EUR

Umsatz:

40.39 Mio. EUR

EBITDA:

-10.2 Mio. EUR

Nettogewinn:

-14.99 Mio. EUR

Gewinn je Aktie:

-0.39 EUR

Schulden:

33.93 Mio. EUR

Liquide Mittel:

25.44 Mio. EUR

Operativer Cashflow:

-8.1 Mio. EUR

Bargeldquote:

2.77

Umsatzwachstum:

-13.74%

Gewinnwachstum:

44.68%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

APYX MEDICAL

Letzte Datenerhebung:

06.11.25

>APYX MEDICAL Kennzahlen

Aktien/ Unternehmen:

Aktien: 37.82 Mio. St.

Frei handelbar: 85.1%

Leerverk. Aktien: 0.83%

Rückkaufquote: -5.53%

Mitarbeiter: 220

Umsatz/Mitarb.: 0.19 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 32.07%

Bewertung:

KGV: -

KGV lG: -

KUV: 2.54

KBV: 15.84

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 31.26%

Gewinnmarge: -37.11%

Operative Marge: -26.46%

Managementeffizenz:

Gesamtkaprendite: -27.93%

Eigenkaprendite: -156.9%

>APYX MEDICAL Peer Group

Es sind 597 Aktien bekannt.

>APYX MEDICAL Chart & Kurs - NASDAQ

>APYX MEDICAL News

06.11.25 - 20:42	Apyx Medical outlines $50.5M–$52.5M 2025 revenue target, signals AYON launch momentum (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.25 - 15:18	Earnings Call Transkript: Apyx Medical übertrifft im 3. Quartal 2025 die Erwartungen bei Gewinn und Umsatz (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.25 - 13:21	Apyx Medical GAAP EPS of -$0.05 beats by $0.05, revenue of $12.9M beats by $0.9M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.10.25 - 13:03

Apyx Medical Corporation to Participate in Upcoming November Investor Conferences (GlobeNewswire EN)

CLEARWATER, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conferences:...

23.10.25 - 14:03

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 (GlobeNewswire EN)

CLEARWATER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the third quarter of fiscal year 2025 will be released before markets open on Thursday, November 6th....

08.08.25 - 20:00	Apyx Medical outlines $50M–$52M 2025 revenue targets as AYON presales surpass expectations and China launch advances (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.08.25 - 22:10

Apyx Medical Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase 100,000 shares of common stock to John Featherstone, Apyx's Vice President, North American Sales as a material inducement to such employee's employment and in accordance with Nasdaq Listing Rule 5635(c)(4)....

07.08.25 - 22:03	Apyx Medical Corporation Reports Second Quarter 2025 Financial Results (GlobeNewswire EN)
	CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its quarter ended June 30, 2025....

30.07.25 - 22:24

Apyx Medical Corporation to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire EN)

CLEARWATER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that management will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, in Boston, MA....

28.07.25 - 14:03	Apyx Medical Corporation Announces Launch of Renuvion® in China (GlobeNewswire EN)
	Strong clinical interest and early procedures completed...

24.07.25 - 22:09

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 (GlobeNewswire EN)

CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the second quarter of fiscal year 2025 will be released after markets closes on Thursday, August 7th....

30.05.25 - 15:01	Renuvion® Brings Real Transformations to the Runway at Miami Swim Week (PR Newswire)
	Highlighting Real Patient Journeys and Empowering Confidence Through Loose Skin Solutions and Body Contouring CLEARWATER, Fla., May 30, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of the proprietary helium plasma and......

13.05.25 - 14:03	Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™ (GlobeNewswire EN)
	The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite...

29.04.25 - 14:03	Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures (GlobeNewswire EN)
	Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin...

24.04.25 - 14:48	Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 (GlobeNewswire EN)
	CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th....

25.03.25 - 14:03	Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener" (PR Newswire)
	Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin CLEARWATER, Fla., March 25, 2025 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the......

13.03.25 - 15:00	Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
	Apyx (APYX) delivered earnings and revenue surprises of 7.69% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...

13.03.25 - 12:06	Apyx Medical GAAP EPS of -$0.12 beats by $0.04, revenue of $14.22M beats by $0.83M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.03.25 - 12:03	Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire EN)
	CLEARWATER, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its fourth quarter and year ended December 31, 2024....

27.02.25 - 14:03	Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025 (GlobeNewswire EN)
	CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Dahingegangenen bleiben mit dem Wesentlichen, womit sie auf uns gewirkt haben, mit uns lebendig, solange wir leben. - Hermann Hesse

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram